Most Read Articles
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
11 Aug 2019
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.

Community-based on par with hospital-based intensive cardiac rehabilitation programme

12 Sep 2018

A 12-week community-based intensive cardiac rehabilitation programme results in significant positive changes in several measures of cardiac risk, with only one adverse event, a recent study has shown.

Individuals seeking either primary or secondary coronary artery disease prevention voluntarily enrolled in the 12-week intensive cardiac rehabilitation programme. The authors obtained data at baseline and 6–12 months after programme completion.

Of the 142 participants (mean age 69 years) who completed the Heart Series between 2012 and 2016, 105 (74 percent) had available follow-up data.

There were statistically significant improvements in mean weight (165–162 lbs; p=0.0005), body mass index (26–25 kg/m2; p=0.001), systolic blood pressure (126–122 mm Hg; p=0.01), diastolic blood pressure (73–70 mm Hg; p=0.0005), total cholesterol (175–168 mg/dL; p=0.03), low-density lipoprotein cholesterol (LDL-C; 100–93 mg/dL; p=0.005), LDL-C/high-density lipoprotein cholesterol (HDL-C) ratio (1.8–1.6; p=0.005), and cholesterol/HDL-C ratio (3.2–3.0; p=0.003).

Although changes in HDL-C, triglycerides and fasting blood glucose did not reach statistical significance, all trended in favourable directions. Furthermore, there were rare adverse cardiovascular disease outcomes (one stent placement; no deaths).

“These results compare favourably with those of hospital-based and academic institutional programmes,” the authors said.

In a previous 3-month, multifactorial cardiac rehabilitation programme that incorporated exercise training, risk factor modification, education and psychosocial support, researchers found that the minority of cardiac rehabilitation patients were women. However, they appeared to benefit equally well from the programme. [Can J Cardiol 2000;16:319-325]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
11 Aug 2019
Intraoperative methylprednisolone does not appear to significantly prevent the incidence of death, cardiac arrest and other injuries in neonates undergoing cardiac surgery with cardiopulmonary bypass, according to a recent study.
11 Aug 2019
Treatment with low-to-standard dose dual combination therapy of blood pressure (BP)-lowering drugs is more effective than standard-dose monotherapy and does not increase withdrawals due to adverse events, a recent study has shown.
20 Jun 2019
Untreated white coat hypertension (WCH), but not treated white coat effect (WCE), may increase the risk for cardiovascular events and all-cause mortality, suggest the results of a systematic review and meta-analysis. Out-of-office blood pressure (BP) monitoring is thus important in the diagnosis and management of hypertension.
06 Aug 2019
Risk factors for 1-year mortality in heart failure (HF) patients significantly differ between those with and without chronic kidney disease (CKD), especially with regard to the use of beta-blockers or diuretics at discharge, according to a study. This suggests that these patients may benefit from individualized therapies.